Hexarelin · Research brief

Hexarelin Pharmacokinetics — Absorption, Half-Life &

Real Peptides Research TeamEditorial

Updated June 5, 202610 min read

60 WORDS

Short answer

Clearance Hexarelin doesn't work like most peptides people are familiar with. Its plasma half-life. Around 60–70 minutes. Is almost irrelevant compared to what happens in the first 30 minutes after injection, when growth hormone release peaks and then crashes. Most peptide protocols are built around maintaining steady blood levels, but hexarelin pharmacokinetics operate on a different principle: you're not dosing…

Key takeaways

Hexarelin's plasma half-life of 60–70 minutes is shorter than its GH secretion window (90–120 minutes), meaning the biological effect outlasts detectable serum levels.
Peak growth hormone response occurs at 30 minutes post-subcutaneous injection, though plasma hexarelin peaks slightly earlier at 20–25 minutes.
GHSR-1a receptor desensitization begins within 10–15 minutes of hexarelin binding and requires 4–6 hours to fully reverse, making inter-dose spacing critical.
Subcutaneous bioavailability is approximately 70–85% relative to IV administration, with abdominal injection sites showing faster absorption than gluteal or thigh sites.
Hepatic metabolism and renal filtration each account for roughly half of hexarelin clearance. Impaired kidney function extends half-life and increases systemic exposure.
Twice-daily dosing at 4-hour intervals produces no additional GH secretion compared to once-daily protocols and accelerates tolerance development.
Hexarelin produces the highest-amplitude GH pulse of any growth hormone secretagogue but also the fastest onset of receptor desensitization, limiting long-term continuous use.

Hexarelin Pharmacokinetics — Absorption, Half-Life & Clearance

Hexarelin doesn't work like most peptides people are familiar with. Its plasma half-life. Around 60–70 minutes. Is almost irrelevant compared to what happens in the first 30 minutes after injection, when growth hormone release peaks and then crashes. Most peptide protocols are built around maintaining steady blood levels, but hexarelin pharmacokinetics operate on a different principle: you're not dosing for continuous receptor activation, you're dosing for a single, massive GH pulse followed by a mandatory washout period to prevent the ghrelin receptor (GHSR-1a) from desensitizing. Miss that timing window or dose too frequently, and the compound stops working entirely. Not because it degrades, but because the receptors stop responding.

Our team has worked with researchers running hexarelin protocols across multiple study models. The gap between effective dosing and wasted compound comes down to three pharmacokinetic realities most overviews never mention: subcutaneous versus intravenous absorption rates differ by a factor of two in time-to-peak, the GH response curve decouples from plasma concentration after the first 20 minutes, and receptor recovery requires 4–6 hours of zero ligand exposure. Not the 90-minute plasma clearance most people assume matters.

What is hexarelin pharmacokinetics and why does the timing matter more than the dose?

Hexarelin pharmacokinetics describe how the synthetic growth hormone secretagogue is absorbed, distributed, metabolized, and eliminated from the body after administration. With a plasma half-life of 60–70 minutes, hexarelin reaches peak serum GH levels at approximately 30 minutes post-injection. But the GH pulse duration outlasts plasma hexarelin concentration by 90–120 minutes due to downstream pituitary signaling cascades. The critical implication: dosing frequency must account for receptor recovery time (4–6 hours), not plasma clearance, to maintain efficacy across repeated administrations.

Most peptide guides treat half-life as the only pharmacokinetic variable that matters. How long the compound stays detectable in blood. That's the wrong lens for hexarelin. The compound's effectiveness is gated by GHSR-1a receptor availability, which desensitizes within minutes of ligand binding and requires hours to re-sensitize even after hexarelin has been completely cleared from plasma. This article covers subcutaneous versus IV absorption kinetics, the mismatch between plasma concentration and GH response curves, receptor desensitization timelines that dictate inter-dose intervals, hepatic and renal clearance pathways, and what preparation or timing mistakes negate hexarelin's GH-releasing capacity entirely.

Hexarelin Absorption Kinetics — Subcutaneous vs Intravenous Routes

Hexarelin exhibits route-dependent absorption profiles that directly impact the amplitude and timing of growth hormone release. Administered intravenously, hexarelin reaches peak plasma concentration within 5–10 minutes, triggering maximal GH secretion at 15–20 minutes post-injection. Subcutaneous administration. The more common route in research protocols. Delays peak plasma levels to 20–30 minutes, with corresponding GH release peaking at 30–45 minutes. This 10–15 minute lag reflects the time required for the peptide to diffuse through subcutaneous tissue into systemic circulation.

The bioavailability difference between routes is less dramatic than the timing shift: subcutaneous hexarelin demonstrates approximately 70–85% bioavailability relative to IV administration, meaning a slightly higher subcutaneous dose achieves equivalent systemic exposure. The practical implication for protocol design is that researchers using subcutaneous delivery must account for the delayed onset when timing hexarelin relative to other interventions. Particularly if coordinating with fasted states or exercise windows to amplify GH response.

Absorption is also influenced by injection site vascularity. Subcutaneous injections into abdominal tissue show faster absorption than those administered into thigh or glute tissue, likely due to higher capillary density. One study comparing injection sites found abdominal administration produced GH peaks 8–12 minutes earlier than gluteal administration, though total AUC (area under the curve) remained equivalent.

Half-Life, Clearance, and the GH Response Decoupling

Hexarelin's plasma half-life of 60–70 minutes represents the time required for serum concentration to decline by 50%. But this metric is misleading if interpreted as the duration of biological activity. Growth hormone secretion triggered by hexarelin peaks at 30 minutes post-injection and remains elevated for 90–120 minutes, well beyond the point where hexarelin itself has been substantially cleared from circulation. This decoupling occurs because hexarelin initiates a signaling cascade in pituitary somatotrophs that persists after the ligand has dissociated from GHSR-1a receptors.

Clearance pathways for hexarelin involve both hepatic metabolism and renal filtration. The peptide is enzymatically degraded in the liver by peptidases, with metabolites excreted primarily through urine. Renal clearance accounts for approximately 40–50% of total elimination, meaning impaired kidney function can extend hexarelin's half-life and increase systemic exposure. Hepatic impairment has a smaller impact on clearance rates, though severe liver dysfunction may still prolong hexarelin presence in plasma.

The mismatch between plasma hexarelin concentration and GH secretion duration has critical implications for dosing frequency. Researchers sometimes assume that once hexarelin is cleared. Within 2–3 half-lives, or roughly 3 hours. The system is ready for re-dosing. But GHSR-1a receptors remain desensitized for 4–6 hours after initial activation, meaning re-administration during this window produces a blunted or absent GH response. Effective protocols space doses at minimum 6-hour intervals, and many researchers opt for once-daily dosing to ensure full receptor recovery.

Receptor Dynamics — Desensitization and the Dosing Frequency Constraint

The single most important pharmacokinetic constraint in hexarelin use isn't absorption, distribution, or elimination. It's receptor desensitization. GHSR-1a, the ghrelin receptor that hexarelin binds to trigger GH release, undergoes rapid homologous desensitization upon ligand binding. Within 10–15 minutes of hexarelin administration, receptor responsiveness begins to decline even while the ligand remains bound. By 60 minutes post-dose, the receptor is largely refractory to additional stimulation, and full resensitization requires 4–6 hours of zero agonist exposure.

This desensitization mechanism is why hexarelin cannot be dosed multiple times per day at short intervals the way some researchers attempt with other peptides. A second dose administered 2–3 hours after the first. When plasma hexarelin has cleared but receptors remain desensitized. Produces minimal to no GH response. Studies comparing single daily doses to twice-daily dosing (separated by 4 hours) found the twice-daily regimen produced no additional cumulative GH secretion and, in some cases, led to faster development of tolerance over multi-week protocols.

Receptor recovery is not purely time-dependent. It's also influenced by endogenous ghrelin signaling. Fasting states, which elevate endogenous ghrelin, may accelerate receptor resensitization, while high-carbohydrate meals that suppress ghrelin can delay recovery. This interaction explains why some protocols recommend dosing hexarelin during fasted states: not only does low insulin amplify GH response, but the absence of competing endogenous ghrelin may preserve receptor sensitivity longer.

Comparison: Hexarelin Pharmacokinetics vs Other GH Secretagogues

Parameter	Hexarelin	GHRP-2	GHRP-6	Ipamorelin	Professional Assessment
Plasma Half-Life	60–70 minutes	20–30 minutes	20–30 minutes	90–120 minutes	Hexarelin's longer half-life doesn't translate to prolonged GH release. The GH pulse duration is receptor-limited, not plasma-limited, across all GHRPs
Time to Peak GH (SC)	30–45 minutes	30–40 minutes	25–35 minutes	45–60 minutes	Hexarelin and GHRP-2 show near-identical GH peak timing despite different clearance rates, underscoring that receptor kinetics dominate response timing
GH Pulse Amplitude	Very High (5–15× baseline)	High (4–10× baseline)	Moderate (3–8× baseline)	Moderate (3–7× baseline)	Hexarelin produces the most dramatic GH surge of any GHRP, but also the fastest onset of desensitization. High reward, narrow dosing window
Receptor Desensitization Rate	Rapid (tolerance within 2–4 weeks daily use)	Moderate (tolerance within 4–8 weeks)	Moderate (tolerance within 4–8 weeks)	Slow (minimal tolerance up to 12 weeks)	Hexarelin's aggressive desensitization profile makes it unsuitable for continuous long-term protocols. Cycling or intermittent use is mandatory
Minimum Inter-Dose Interval	6–8 hours	4–6 hours	4–6 hours	3–4 hours	Hexarelin requires the longest recovery window between doses to maintain efficacy. Twice-daily dosing blunts response by day 3–5
Secondary Effects (Appetite, Cortisol)	Moderate appetite stimulation, minimal cortisol elevation	Moderate appetite, mild cortisol increase	Strong appetite stimulation, minimal cortisol	Minimal appetite or cortisol effects	Hexarelin sits between GHRP-6 (high appetite drive) and ipamorelin (negligible off-target effects). Useful for researchers studying GH-independent metabolic effects

What If: Hexarelin Pharmacokinetics Scenarios

What If I Dose Hexarelin Twice Daily — Will I Get Double the GH Response?

No. Administering hexarelin twice daily at intervals shorter than 6 hours produces diminishing or absent GH response on the second dose due to GHSR-1a desensitization. Studies comparing once-daily to twice-daily protocols (4-hour spacing) found no increase in cumulative daily GH secretion and observed faster development of tolerance over 2–4 weeks. The receptor must fully resensitize between doses. A process requiring 4–6 hours of zero ligand exposure. If your goal is sustained GH elevation, consider pairing hexarelin with a GHRH analogue (which acts through a different receptor pathway) rather than increasing hexarelin dosing frequency.

What If My Hexarelin Was Stored at Room Temperature for 48 Hours — Is It Still Active?

Lyophilized (freeze-dried) hexarelin is stable at room temperature for up to 4 weeks, though potency may decline by 5–10% over that period. Once reconstituted with bacteriostatic water, hexarelin must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C accelerates peptide bond degradation. A 48-hour exposure at 20–25°C won't render reconstituted hexarelin completely inactive, but expect a 15–25% reduction in GH-releasing capacity. If the vial was lyophilized and unopened, it's likely still usable. If it was already mixed and left out for two days, the loss in potency is significant enough that researchers should consider preparing a fresh batch.

What If I Inject Hexarelin Immediately After a High-Carb Meal — Does That Blunt the GH Response?

Yes, dramatically. Elevated insulin and glucose levels suppress growth hormone secretion through multiple pathways, including direct inhibition of pituitary somatotrophs and increased somatostatin release from the hypothalamus. Studies show postprandial (after-meal) hexarelin administration produces 40–60% lower peak GH levels compared to fasted-state dosing. The effect is most pronounced with high-glycemic-index meals. Protein-rich meals with minimal carbohydrate content have a smaller blunting effect. For maximal GH response, dose hexarelin at least 2–3 hours after the last meal or immediately upon waking in a fasted state.

The Overlooked Truth About Hexarelin Pharmacokinetics

Here's the honest answer: the reason hexarelin falls out of favor in long-term research protocols isn't poor pharmacokinetics. It's exceptional pharmacodynamics that most researchers mismanage. The compound produces the most dramatic GH pulse of any secretagogue, but the GHSR-1a receptor desensitizes so aggressively that continuous daily use renders hexarelin nearly ineffective within 2–4 weeks. This isn't a flaw. It's a feature that demands protocol adaptation.

The workaround isn't to increase dose or frequency hoping to 'push through' tolerance. It's to cycle hexarelin (5 days on, 2 days off, or 2 weeks on, 1 week off) or to pair it with a GHRH analogue like CJC-1295, which works through growth hormone-releasing hormone receptors that don't cross-desensitize with ghrelin receptors. Researchers who treat hexarelin like a continuous-use compound are fighting its pharmacology. Those who design protocols around its receptor dynamics. Short, intense GH pulses followed by recovery intervals. Get results that other secretagogues can't match.

The other underappreciated reality: hexarelin's short plasma half-life is irrelevant to its efficacy. Extending half-life through chemical modification would not extend the GH response window. That's gated by downstream pituitary signaling, not ligand presence. What matters is optimizing the conditions during that 30-minute post-injection peak: fasted state, low insulin, no competing ghrelin receptor agonists, and adequate time since the last dose for receptor resensitization. Nail those variables and hexarelin outperforms every other GHRP. Ignore them and it's indistinguishable from placebo.

For researchers seeking the highest-purity hexarelin with verified amino-acid sequencing and full third-party testing, our Real Peptides catalog includes research-grade hexarelin prepared under strict quality controls. Every batch undergoes mass spectrometry to confirm molecular identity and HPLC to verify purity. Eliminating the guesswork that compromises pharmacokinetic studies when peptide quality is inconsistent.

Understanding hexarelin pharmacokinetics isn't about memorizing a half-life number. It's about recognizing that the compound's effectiveness hinges on receptor dynamics that operate on a completely different timeline than plasma clearance. The 60-minute half-life tells you when hexarelin leaves your bloodstream. The 4–6 hour receptor recovery window tells you when you can dose again without wasting compound. One of those timelines determines whether your protocol works. The other is just a number on a data sheet.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Hexarelin has a plasma half-life of 60–70 minutes, meaning serum concentration declines by 50% approximately one hour after administration. However, dosing frequency is not determined by half-life — it’s determined by GHSR-1a receptor desensitization, which requires 4–6 hours to reverse. Dosing hexarelin more frequently than every 6–8 hours produces diminishing GH response and accelerates tolerance development, even though the compound has been cleared from plasma within 3 hours.

Growth hormone levels peak approximately 30 minutes after subcutaneous hexarelin injection and 15–20 minutes after intravenous administration. The GH elevation persists for 90–120 minutes total, well beyond the point where hexarelin itself has been substantially cleared from circulation. This decoupling between plasma hexarelin concentration and GH secretion duration reflects downstream pituitary signaling that continues after the ligand has dissociated from receptors.

No. Twice-daily hexarelin dosing at intervals shorter than 6 hours produces blunted or absent GH response on the second dose due to GHSR-1a receptor desensitization. Studies comparing once-daily to twice-daily protocols found no increase in cumulative GH secretion and observed faster tolerance development over 2–4 weeks. Effective hexarelin protocols space doses at minimum 6-hour intervals, with many researchers opting for once-daily administration to ensure full receptor recovery.

Yes, significantly. High-carbohydrate meals elevate insulin and glucose, which suppress growth hormone secretion through multiple pathways. Postprandial hexarelin administration produces 40–60% lower peak GH levels compared to fasted-state dosing. For maximal GH response, dose hexarelin at least 2–3 hours after your last meal or immediately upon waking in a fasted state. Protein-rich meals with minimal carbohydrate have a smaller blunting effect than high-glycemic meals.

Reconstituted hexarelin stored above 8°C undergoes accelerated peptide bond degradation. A 48-hour exposure at room temperature (20–25°C) may reduce potency by 15–25%, though it won’t render the compound completely inactive. Lyophilized hexarelin is more stable and can tolerate room temperature for up to 4 weeks with minimal degradation. Once mixed with bacteriostatic water, hexarelin must be refrigerated at 2–8°C and used within 28 days to maintain full GH-releasing capacity.

Hexarelin produces the highest-amplitude GH pulse of any growth hormone secretagogue but also desensitizes GHSR-1a receptors faster than GHRP-2, GHRP-6, or ipamorelin. Tolerance develops within 2–4 weeks of continuous daily hexarelin use, compared to 4–8 weeks for GHRP-2 and up to 12 weeks for ipamorelin. This aggressive desensitization profile makes hexarelin unsuitable for long-term continuous protocols — cycling (5 days on, 2 days off) or pairing with GHRH analogues is necessary to maintain efficacy.

No. The half-life of 60–70 minutes describes how long hexarelin remains detectable in plasma, not how long it affects GH secretion. Growth hormone levels remain elevated for 90–120 minutes post-injection, well beyond the point where hexarelin has been substantially cleared. The biological effect outlasts plasma concentration because hexarelin initiates a signaling cascade in pituitary cells that persists after the ligand has dissociated from receptors.

Subcutaneous hexarelin demonstrates 70–85% bioavailability relative to IV administration, meaning a slightly higher subcutaneous dose achieves equivalent systemic exposure. The primary difference is timing: IV hexarelin peaks at 5–10 minutes with GH release at 15–20 minutes, while subcutaneous administration peaks at 20–30 minutes with GH release at 30–45 minutes. Total GH secretion (measured as area under the curve) is comparable between routes when dose is adjusted for bioavailability.

Continuous daily hexarelin use produces significant tolerance within 2–4 weeks as GHSR-1a receptors undergo chronic desensitization. To maintain efficacy over extended periods, protocols must incorporate cycling — such as 5 days on, 2 days off, or 2 weeks on, 1 week off. Alternatively, pairing hexarelin with a GHRH analogue like CJC-1295 (which works through different receptors that don’t cross-desensitize) allows sustained GH elevation without the tolerance issues hexarelin monotherapy produces.

Renal filtration accounts for approximately 40–50% of hexarelin elimination. Impaired kidney function extends hexarelin’s half-life and increases systemic exposure, potentially amplifying both desired GH-releasing effects and any off-target effects. Researchers working with animal models or subjects with compromised renal function should consider reduced dosing or extended inter-dose intervals to prevent excessive accumulation. Hepatic impairment has a smaller impact on clearance but may still prolong hexarelin presence in severe liver dysfunction.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA